Ramez Khoury, MD
Gastroenterology · Janesville, WINPI 1780743682
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,408 of the $13,247 with a category attached, or 86.1%. 24 manufacturers reported payments, led by AbbVie at 27.6% of the total. 2025 is the largest year on record at $4,765, 3.9 times the $1,237 reported in 2019. Among gastroenterology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $58.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$3K
- Gilead$2K
- Madrigal Pharmaceuticals$617
- Bristol Myers Squibb$572
- E.r. Squibb & Sons, L.L.C.$547
- plus $3K from 18 others
What the payments were for
- Consulting fees$1,65012%
- Travel & lodging$1121%
- Food & beverage$11,40886%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $3,661 |
| Johnson & Johnson | 23 | $2,888 |
| Gilead | 43 | $1,823 |
| Madrigal Pharmaceuticals | 6 | $617 |
| Bristol Myers Squibb | 20 | $572 |
| E.r. Squibb & Sons, L.L.C. | 5 | $547 |
| Sanofi | 6 | $445 |
| Janssen Scientific Affairs, LLC | 4 | $405 |
| Phathom Pharmaceuticals, Inc. | 3 | $349 |
| Regeneron Healthcare Solutions, Inc. | 4 | $329 |
| Lilly USA, LLC | 4 | $260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $249 |
| Ardelyx, Inc. | 2 | $220 |
| Regeneron | 1 | $150 |
| Novo Nordisk | 2 | $144 |
| Boston Scientific | 2 | $130 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Capsovision, Inc. | 1 | $91 |
| QOL Medical, LLC | 1 | $84 |
| UCB, Inc. | 4 | $75 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Pfizer | 1 | $16 |
| Merck | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,247 in reported general payments places this provider in the 90th percentile of 285 gastroenterology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $166,047 |
| Humira PenAdalimumab | 13 | $104,753 |
| CreonLipase/Protease/Amylase | 19 | $67,825 |
| XifaxanRifaximin | 17 | $49,536 |
| LinzessLinaclotide | 42 | $36,137 |
| Mesalamine | 38 | $31,624 |
| VemlidyTenofovir Alafenamide | 11 | $15,938 |
| Colestipol Hcl | 76 | $7,679 |
| Ursodiol | 30 | $5,952 |
| Budesonide DrBudesonide | 20 | $2,224 |
| Budesonide EcBudesonide | 16 | $2,191 |
| Omeprazole | 175 | $1,757 |
| Balsalazide Disodium | 11 | $1,388 |
| Mesalamine ErMesalamine | 17 | $1,298 |
| Pantoprazole Sodium | 56 | $851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,661 | $103,96161 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $49,53617 claims |
| GileadVemlidy | $1,823 | $15,93811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 gastroenterology providers in Wisconsin.
Other gastroenterology in Janesville
- Daniel SteinMilwaukee$227K
- Amir PatelSheboygan$137K
- Poonam Beniwal-PatelMilwaukee$108K
- Lilani PereraMequon$95K
- Freddy CalderaMadison$72K
- Matthew PellerMilwaukee$63K
- Susan LepinskiMadison$61K
- Chetan MittalMilwaukee$53K
- Pedro Palacios ArguetaEau Claire$53K
- Patrick SanvansonMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.